StrataXRT

PreclinicalSmall molecule

MMayo Clinic

StrataXRT is one of 17 small molecule programs targeting Dermatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DermatitisActive, not recruiting

DermatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Dermatitis

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

1 2

Anzupgo

Daliresp

Nizoral

Kenalog

BBausch Health Americas, Inc.

Approved

—6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Rinvoq

1 8

JAK Inhibitor

FFred Hutchinson Cancer Center

Phase 2

1 9

Acanya

Pfizer

Preclinical

1 10

Voltaren

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dermatitis1 trial

Feasibility in the Prophylaxis of Radiation Dermatitis Severity

Terminated·MMayo Clinic··NCT04715386·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for StrataXRT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — StrataXRT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for StrataXRT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMayo Clinic

StrataXRT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dermatitis1 trial

References

Drug Info

Quick Facts

Related News